Prediction of Cognitive Progression in Individuals with Mild Cognitive Impairment Using Radiomics as an Improvement of the ATN System: A Five-Year Follow-Up Study
Aged, 80 and over
Male
Amyloid beta-Peptides
tau Proteins
Peptide Fragments
3. Good health
Neuroimaging and Head & Neck
03 medical and health sciences
Cognition
0302 clinical medicine
Alzheimer Disease
Disease Progression
Humans
Cognitive Dysfunction
Female
Biomarkers
Aged
Follow-Up Studies
DOI:
10.3348/kjr.2021.0323
Publication Date:
2022-01-03T03:12:21Z
AUTHORS (8)
ABSTRACT
To improve the N biomarker in amyloid/tau/neurodegeneration system by radiomics and study its value for predicting cognitive progression individuals with mild impairment (MCI). A group of 147 healthy controls (HCs) (72 male; mean age ± standard deviation, 73.7 6.3 years), 197 patients MCI (114 72.2 7.1 128 Alzheimer's disease (AD) (74 8.4 years) were included. Optimal A, T, biomarkers discriminating HC AD selected using receiver operating characteristic (ROC) curve analysis. model containing comprehensive information whole cerebral cortex deep nuclei was established to create a new biomarker. Cerebrospinal fluid (CSF) evaluated determine optimal or T biomarkers. All followed up until conversion at least 60 months. The predictive radiomics-based analyzed Kaplan-Meier estimates log-rank test. showed an ROC area 0.998 between HC. CSF Aβ42 p-tau proteins identified as biomarkers, respectively. For on continuum, isolated A+ indicator stability, while abnormalities N, separately simultaneously, indicated high risk progression. suspected non-Alzheimer's pathophysiology, T+ appearance N+ AD. We proposed improved that could help identify who are higher In addition, we clarified single A/T/N MCI.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (38)
CITATIONS (4)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....